Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
The net profit margin is 0.00% as of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
NET PROFIT MARGIN
0.00%
NET PROFIT MARGIN AVG TTM
0.00%
NET PROFIT MARGIN AVG 3Y
0.00%
NET PROFIT MARGIN AVG 5Y
0.00%
NET PROFIT MARGIN AVG 10Y
0.00%
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 784 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
Larimar Therapeutics, Inc.
Market Cap
$294.51M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$300.61M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
-6520.67%
5Y Avg
-12425.66%
Market Cap
$288.39M
Net Profit Margin
-103.29%
TTM Avg
-83.69%
3Y Avg
-107.92%
5Y Avg
-85.90%
Market Cap
$287.37M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
-348.45%
5Y Avg
-232.30%
Market Cap
$286.50M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$286.40M
Net Profit Margin
-246.42%
TTM Avg
611.54%
3Y Avg
-783.13%
5Y Avg
-1134.34%
Market Cap
$285.98M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$304.43M
Net Profit Margin
-145.12%
TTM Avg
-145.12%
3Y Avg
-145.12%
5Y Avg
-145.12%
Market Cap
$282.30M
Net Profit Margin
0.00%
TTM Avg
-6.08%
3Y Avg
-1303.66%
5Y Avg
-1073.20%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Larimar Therapeutics, Inc. (LRMR) | $294.51M | 0.00% | 0.00% | 0.00% | 0.00% |
| Benitec Biopharma Inc. (BNTC)vs › | $300.61M | 0.00% | 0.00% | -6520.67% | -12425.66% |
| Standard BioTools Inc. (LAB)vs › | $288.39M | -103.29% | -83.69% | -107.92% | -85.90% |
| Sagimet Biosciences Inc. (SGMT)vs › | $287.37M | 0.00% | 0.00% | -348.45% | -232.30% |
| Indaptus Therapeutics, Inc. (INDP)vs › | $286.50M | 0.00% | 0.00% | 0.00% | 0.00% |
| Abeona Therapeutics Inc. (ABEO)vs › | $286.40M | -246.42% | 611.54% | -783.13% | -1134.34% |
| BridgeBio Oncology Therapeutics Inc. (BBOT)vs › | $285.98M | 0.00% | 0.00% | 0.00% | 0.00% |
| Mobia Medical, Inc. Common Stock (MOBI)vs › | $304.43M | -145.12% | -145.12% | -145.12% | -145.12% |
| Fulcrum Therapeutics, Inc. (FULC)vs › | $282.30M | 0.00% | -6.08% | -1303.66% | -1073.20% |
| Aurora Cannabis Inc. (ACB)vs › | $279.98M | -38.13% | -18.76% | -107.01% | -249.44% |
Operating Margin
0.0%
Net Profit Margin
0.0%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | 0.00% |
| 2019-03-31 | 0.00% |
| 2018-12-31 | 0.00% |
| 2018-09-30 | 0.00% |
| 2018-06-30 | 0.00% |
| 2018-03-31 | 0.00% |
| 2017-12-31 | 0.00% |
| 2017-09-30 | 0.00% |
| 2017-06-30 | 0.00% |
| 2017-03-31 | 0.00% |
| 2016-12-31 | 0.00% |
| 2016-09-30 | 0.00% |
| 2016-06-30 | 0.00% |
| 2016-03-31 | 0.00% |
| 2015-12-31 | 0.00% |
| 2015-09-30 | 0.00% |
| 2015-06-30 | 0.00% |
| 2015-03-31 | 0.00% |
| 2014-12-31 | 0.00% |
| 2014-09-30 | 0.00% |
| 2014-06-30 | 0.00% |
